Gene therapy

#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines

Optimising AAV capsid purification through improved analytics

Listen to this article on the DDW Podcast: Svea Cheeseman, Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. As demand for AAV gene therapies increases, it is… Read More

#Exclusive Content

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

Keep up to date: DDW Highlights 30 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Cell and gene therapies have been making the news this week, as… Read More

#News

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

This week in drug discovery (23-27 January)

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

#News

Gene therapy
#Cell and gene therapy #Gene therapy #Investment #Muscular dystrophy #Seed funding #Start-ups

$5 million raised towards gene therapies for muscular diseases

Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.  The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.  “Built on decades… Read More

#Business & Investment #News #Start-up Zone

EMA
#AAV #Cell and gene therapy #European Medicines Agency #Forge Biologic #Gene therapy #Priority Review

EMA prioritises AAV gene therapy for Krabbe disease

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up… Read More

#News #Regulatory

Child with cystic fibrosis on ventilator
#Cell and gene therapy #Cystic fibrosis #European Commission #Gene therapy #Krystal Biotech #Orphan drugs

Gene therapy for cystic fibrosis receives EC orphan drug designation

The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).  KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered… Read More

#News #Regulatory

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Guide

Exclusive insight into cell and gene therapy

Download this exclusive cell and gene therapy guide to learn about: The successes of cell and gene therapies plus the biggest questions facing the sector Expert views on the challenges and opportunities for cell and gene therapies in 2023 Understanding future road maps of cell and gene therapies Why there… Read More

#DDW eBooks

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News

Virus-like particles
#Biopharmaceuticals #Cell and gene therapy #Collaboration #Gene delivery #Gene therapy #Partnership #Vector BioPharma

Vector and iBET collaborate to accelerate gene delivery platform

Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform.  Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins.  Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading… Read More

#Business & Investment #News

Blood in a Petri dish
#BioMarin Pharmaceuticals #Cell and gene therapy #Gene therapy #Haemophilia #Orphan drugs #Phase III trial

Haemophilia one-time gene therapy effective for three years

An investigational one-time gene therapy for the treatment of adults with severe haemophilia A has been proven to be effective for more than three years from treatment.  BioMarin Pharmaceutical revealed the positive results from its ongoing global Phase III GENEr8-1 study of Roctavian (valoctocogene roxaparvovec).  … Read More

#News #Trending News

AAV gene therapy
#AAV #Animal models #CANbridge Pharmaceuticals #Cell and gene therapy #China #Gene therapy #License agreement #Muscular dystrophy

Chinese biotech company consolidates gene therapy portfolio

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School.  Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along… Read More

#News

Gene therapy for haemophilia
#Cell and gene therapy #CHMP #CSL #Europe #Gene therapy #Haemophilia

First gene therapy for haemophilia B gets go ahead in Europe

The first gene therapy for haemophilia B could soon be available to patients in Europe following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).  The CHMP has recommended conditional marketing authorisation of CSL’s etranacogene dezaparvovec, a one-time gene therapy for the treatment of appropriate adults… Read More

#News #Regulatory #Trending News

Epidermolysis bullosa patient has foot bandaged
#Clinical trial #Dermatology #Epidermolysis bullosa #Gene delivery #Gene therapy

‘Life-changing’ topical gene therapy gel heals EB wounds

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB).  People with dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. It’s an intensely painful condition, and medical treatment… Read More

#News #Trending News

#Biologics / Biotechnology #Cancer research #Collaboration #Europe #Gene therapy #Lung cancer

International consortium launches €12.8 million lung cancer project

Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.   The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More

#Cancer Research #News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News